Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Financing Activities (2016 - 2026)

Champions Oncology has reported Cash from Financing Activities over the past 17 years, most recently at -$36000.0 for Q1 2026.

  • Quarterly results put Cash from Financing Activities at -$36000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Jan 2026 was $86000.0 (down 47.88% YoY), and the annual figure for FY2025 was $170000.0, up 132.26%.
  • Cash from Financing Activities for Q1 2026 was -$36000.0 at Champions Oncology, down from $168000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CSBR hit a ceiling of $239000.0 in Q4 2024 and a floor of -$590000.0 in Q3 2023.
  • Median Cash from Financing Activities over the past 5 years was -$23000.0 (2025), compared with a mean of -$10285.7.
  • Biggest five-year swings in Cash from Financing Activities: surged 221.43% in 2022 and later tumbled 568.75% in 2023.
  • Champions Oncology's Cash from Financing Activities stood at $86000.0 in 2022, then skyrocketed by 55.81% to $134000.0 in 2023, then soared by 78.36% to $239000.0 in 2024, then fell by 29.71% to $168000.0 in 2025, then tumbled by 121.43% to -$36000.0 in 2026.
  • The last three reported values for Cash from Financing Activities were -$36000.0 (Q1 2026), $168000.0 (Q4 2025), and -$14000.0 (Q3 2025) per Business Quant data.